Common Polymorphisms in MTNR1B, G6PC2 and GCK Are Associated with Increased Fasting Plasma Glucose and Impaired Beta-Cell Function in Chinese Subjects

Abstract

Background

Previous studies identified melatonin receptor 1B (MTNR1B), islet-specific glucose 6 phosphatase catalytic subunit-related protein (G6PC2), glucokinase (GCK) and glucokinase regulatory protein (GCKR) as candidate genes for type 2 diabetes (T2D) acting through elevated fasting plasma glucose (FPG). We examined the associations of the reported common variants of these genes with T2D and glucose homeostasis in three independent Chinese cohorts.

Methodology/Principal Findings

Five single nucleotide polymorphisms (SNPs), MTNR1B rs10830963, G6PC2 rs16856187 and rs478333, GCK rs1799884 and GCKR rs780094, were genotyped in 1644 controls (583 adults and 1061 adolescents) and 1342 T2D patients. The G-allele of MTNR1B rs10830963 and the C-alleles of both G6PC2 rs16856187 and rs478333 were associated with higher FPG (0.0034<P<6.6×10−5) in healthy controls. In addition to our previous report for association with FPG, the A-allele of GCK rs1799884 was also associated with reduced homeostasis model assessment of beta-cell function (HOMA-B) (P = 0.0015). Together with GCKR rs780094, the risk alleles of these SNPs exhibited dosage effect in their associations with increased FPG (P = 2.9×10−9) and reduced HOMA-B (P = 1.1×10−3). Meta-analyses strongly supported additive effects of MTNR1B rs10830963 and G6PC2 rs16856187 on FPG.

Conclusions/Significance

Common variants of MTNR1B, G6PC2 and GCK are associated with elevated FPG and impaired insulin secretion, both individually and jointly, suggesting that these risk alleles may precipitate or perpetuate hyperglycemia in predisposed individuals.

About the Authors:

Claudia Ha Ting Tam

Contributed equally to this work with: Claudia Ha Ting Tam, Janice Sin Ka Ho

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Janice Sin Ka Ho

Contributed equally to this work with: Claudia Ha Ting Tam, Janice Sin Ka Ho

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Ying Wang

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Heung Man Lee

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Vincent Kwok Lim Lam

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Soren Germer

Affiliation: Roche Pharmaceuticals, Nutley, New Jersey, United States of America

Mitchell Martin

Affiliation: Roche Pharmaceuticals, Nutley, New Jersey, United States of America

Wing Yee So

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Ronald Ching Wan Ma

* E-mail: [email protected]

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Juliana Chung Ngor Chan

Affiliations Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Maggie Chor Yin Ng

Current address: Department of Pediatrics, Section on Medical Genetics, and Centers for Human Genomics and Diabetes Research, Wake Forest University School of Medicine, Wake Forest, North Carolina, United States of America

Affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong, Special Administrative Region, People's Republic of China

Introduction

Elevated fasting plasma glucose (FPG) level is an important risk factor contributing to cardiometabolic diseases. Impaired fasting glucose, defined as FPG from 5.6 to 6.9 mmol/l (ADA criteria) [1] or 6.1 to 6.9 mmol/l (WHO criteria) [2], is associated with increased risk of diabetes and cardiovascular disease [3], [4]. Adequate insulin secretion and sensitivity is critical in the maintenance of euglycemia [5]. FPG level is shown to be moderately heritable in twin and family studies (heritability estimate h2 = 0.20–0.28 [6], [7], [8]. Recent genome-wide association studies (GWAS) have uncovered a few loci associated with FPG, including genes encoded for melatonin receptor 1B (MTNR1B), glucose-6-phospate catalytic subunit 2 (G6PC2), glucokinase (GCK) and glucokinase regulatory protein (GCKR) [9]. Surprisingly, these genes only demonstrated modest or weak association with type 2 diabetes (T2D) [9], [10], , despite a close interplay between T2D and high FPG level. Although most T2D genes are implicated in beta-cell function [12], high FPG level from other causes can worsen insulin secretion or sensitivity by setting up a vicious cycle via glucotoxicity [13].

MTNR1B, GCK and G6PC2 proteins are expressed in the human beta cells [14], [15], [16]. MTNR1B encodes a high affinity receptor for melatonin, a hormone primarily secreted by the pineal gland to regulate circadian rhythm and sleep cycles [17]. Plasma melatonin follows an opposite circadian rhythm to plasma insulin and glucose, rising by night and falling by day, which suggests that melatonin may affect insulin release and glucose level via its islet-specific receptor [18]. Large scale association studies [9], [10], [14] suggested that two common MTNR1B SNPs rs1387153 and rs10830963 (r2 = 0.7 in Europeans) may affect insulin secretion and glucose homeostasis.

Glucokinase (encoded by GCK) is a glucose-sensing enzyme that determines the threshold for glucose-stimulated-insulin-secretion (GSIS) in islets, and controls gluconeogenesis and glycogen synthesis in hepatocytes [15]. The hepatic activity of GCK is inhibited by its regulatory protein GCKR in a dose-dependent manner, which competes with glucose for binding site [19]. Two GCKR variants rs780094 and rs1260326 (r2 = 0.93 in Europeans) are associated with HOMA-IR, FPG and triglyceride levels [20], [21]. A functional study showed that this effect was mediated through reduced repression on GCK [22].

The GCK variant rs1799884 is associated with higher FPG in Caucasian and Chinese cohorts [23], [24], [25], and rare GCK mutations confer a form of maturity-onset diabetes of the young (MODY 2) characterized by hyperglycemia [26]. Glucose-6-phospate catalytic subunit 2 (encoded by G6PC2) is proposed to counteract pancreatic GCK activity by competing for glucose usage [16]. G6PC2-null mice demonstrated a ∼15% reduction in FPG level [27], and two SNPs rs560887 and rs563694 were repeatedly associated with hyperglycemia in Europeans [10], [28], [29], [30]. However, these two variants are nearly monomorphic in Asians, so Hu et al. adopted a tagSNP approach and reported a FPG-associated SNP rs16856187 in Chinese [31].

Based on their common effects on FPG levels and co-presence in the beta-cell and liver, variants in MTNR1B, GCK, G6PC2 and GCKR are hypothesized to have interactions or joint effects. Bouatia-Naji et al. have reported their additive effects on FPG [9], [32], and we have previously shown that a variant in GCKR modifies the association between GCK and FPG [24]. In this study, we aimed to validate the reported dosage effects on FPG in a Chinese cohort, and examined their associations with insulin secretion and sensitivity as estimated by HOMA-IR and HOMA-B indices.

Materials and Methods

Subjects

We have previously described the study design, ascertainment, inclusion criteria and phenotyping procedures of subjects included in this study [33]. All subjects were of southern Han Chinese ancestry residing in Hong Kong. The control cohort consists of 1644 subjects with FPG<6.1 mmol/l ascertained from a) 583 hospital staff and volunteers from a community-based health screening program (mean age 41.4±10.5 years, 45% male) and b) 1061 adolescents from a community-based school survey (mean age 15.4±1.9 years, 45% male). A subgroup of 420 adult controls also underwent a 75g oral glucose tolerance test (OGTT). The case cohort consists of 1342 unrelated T2D patients (mean age 50.5±13.7 years, 41% male, mean duration of T2D 6.1±6.5 years) selected from the Hong Kong Diabetes Registry (HKDR). T2D was diagnosed according to the 1998 World Health Organization (WHO) criteria. Patients with classic type 1 diabetes with acute ketotic presentation or continuous requirement of insulin within 1 year of diagnosis were excluded. The clinical characteristics of subjects in the three cohorts are summarized in Table 1. Written informed consent was obtained from all adult subjects and parents of the adolescents while the adolescents gave verbal consent. This study was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong.

[Figure omitted. See PDF.]

Table 1. Clinical and metabolic characteristics of 1644 healthy Chinese adults and adolescents and 1342 T2D patients.

https://doi.org/10.1371/journal.pone.0011428.t001

Clinical studies

All study subjects were examined in the morning after an overnight fast. Anthropometric measurements including body weight and height were documented. Fasting blood samples were collected for DNA extraction and measurements of FPG and fasting plasma insulin (FPI). Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as (FPI×FPG)22.5, and homeostasis model assessment of beta-cell function (HOMA-B) was calculated as FPI×20(FPG - 3.5) [34]. Insulinogenic index was calculated as (PI during OGTT for 30 min - 0 min)(PG during OGTT for 30 min - 0 min) [35]. Data were discarded if PI or PG level at 0 min were higher than that of 30 min. Insulin sensitivity index (ISI) was estimated using the formula proposed by Matsuda and DeFronzo [36]: 10,000[FPG×FPI×(mean PG during OGTT)×(mean PI during OGTT)]. Insulin disposition index (IDI) was calculated as ISI×insulinogenic index100 [36].

Genotyping

We genotyped five SNPs in four genes including MTNR1B rs10830963, G6PC2 rs16856187 and rs478333, GCK rs1799884 and GCKR rs780094 in all study subjects due to their reported associations with FPG, beta-cell function and T2D [29], [31], [32], except for G6PC2 rs478333. Although G6PC2 rs560887 [28], [30] and G6PC2 rs563694 [29] showed association with FPG in Caucasian populations, both of their corresponding minor allele frequencies (MAF) are rare in Chinese population (0.006 and 0.012 in HapMap CHB for rs560887 and rs563694, respectively). Additionally, Shanghai study [31] found that rs16856187 showed the strongest signal for both T2D and FPG. To clarify these inter-ethnic differences, we genotyped rs16856187 and another nearby SNP rs478333 located in the 3′ flanking region, which has common allele frequencies in both Chinese (0.29 in HapMap CHB) and Caucasian (0.49 in HapMap CEU) populations. We did not test for associations for all tagging SNPs of the respective genes. Genotyping on genomic DNA was performed either at deCODE Genetics using the Centaurus (Nanogen) platform or at the McGill University and Genome Quebec Innovation Centre using the Sequenom MassARRAY platform (San Diego, CA, USA). The concordance rate for part of the samples genotyped on both platforms is >99%. All SNPs were in Hardy-Weinberg equilibrium (P>0.05) in control cohorts using the exact test implemented in PLINK [37]. The overall genotype call rates were >96% and the minor allele frequencies (MAF) in normal controls (MAF of MTNR1B rs10830963 = 0.44 for both adult and adolescent controls; G6PC2 rs16856187 and rs478333 = 0.30 and 0.35, respectively for both adult and adolescent controls; GCK rs1799884 = 0.16 and 0.19 in adult and adolescent controls, respectively) were comparable with the HapMap CHB data (0.48 for MTNR1B rs10830963; 0.28 and 0.29 for G6PC2 rs16856187 and rs478333, respectively; 0.20 for GCK rs1799884), except the one of GCKR rs780094. MAFs of GCKR rs780094 in our data (0.46 for both adult and adolescent cohorts) were lower than seen in the HapMap CHB (0.60), but they were similar to the frequency reported in a group of Han Chinese (0.44) study [21].

Systematic Review

A systematic literature search was performed according to the MOOSE guidelines [38] for the meta-analysis of observational studies. The description of studies and details of the literature search process are outlined in the table (Table S1) and the flow chart (Figure S1), respectively. We searched the PubMed database from inception to January 2010 for association studies between fasting glucose and MTNR1B or G6PC2 genes. The keywords used were MTNR1B, G6PC2 and fasting glucose. We restricted our analysis to human studies, and placed no language restriction. We included studies if they (a) reported the association results for subjects in case-control or population-based studies; (b) genotyped MTNR1B rs10830963, G6PC2 rs560887 or rs16856187 and measured fasting glucose levels for the studied subjects; (c) presented results as mean ± SD with sample size stratified by genotypes with or without adjustment for covariate. We excluded studies if they (a) were reviews or abstract; (b) were duplicate reports on previously published studies; (c) did not provide sufficient information for computation of a quantitative effect estimate of the relationship between FPG and genetic variants.

Statistical analysis

All data are presented as percentage, mean ± SD or median (interquartile range), as appropriate. Insulinogenic index, FPI, HOMA-IR, HOMA-B, ISI and IDI were logarithmically transformed due to skewed distributions. Each trait was winsorized separately in adult and adolescent cohorts by replacing extreme values with 4 standard deviations from the mean. Less than 0.2% of data were replaced.

Within each control cohort, associations between genotypes and phenotypic traits were tested by multivariate linear regression adjusted for sex, age, and BMI (where appropriate) under the additive genetic model. In the combined analysis, an additional dummy variable “study cohort” coded as 0 for adult controls and 1 for adolescent controls was included in the regression model. Multiple testing of phenotypic traits and SNPs were corrected by controlling the false discovery rate (FDR) using the Benjamini-Hochberg approach [39]. An alternative method for controlling multiple testing is developed by Conneely and Boehnke [40], which accounts for correlation both among SNPs and among phenotypes and is less conservative than FDR. To assess gene-gene interaction effects on phenotypic traits, linear regression analyses including the main and pairwise interaction effects of SNPs under an additive genetic model were applied. The joint effects of the SNPs was assessed by calculating the estimated marginal mean with 95% confidence intervals (CIs) in a general linear model (including sex, age, BMI and study cohort as covariates), categorized by the number of risk alleles assuming an additive genetic model. Risk alleles were defined as alleles that increased fasting plasma glucose described either in literature or in the present study. The significance of the trend was tested by linear regression using the number of risk alleles carried as an independent variable.

Frequencies of genotypes and number of risk alleles between T2D cases and healthy controls were compared using logistic regression adjusted for age, sex and BMI. Odd ratios (ORs) with 95% CIs were presented.

Meta-analyses for the association of FPG were calculated based on the Hedges g statistic which was used to calculate the standardized mean difference (SMD) across studies under the fixed effects model. To account for heterogeneity of SMDs across studies (Cochran's Q statistic P<0.1), the overall effect size (SMD) under the random effects model was reported, in which both random variations within and between different studies were incorporated [41].

We estimated study power using genetic power calculator [42]. Assuming an additive model with the frequencies of 0.41 [43] for the G-allele of MTNR1B rs10830963, 0.30 [31] for the C-alleles of G6PC2 rs16856187, 0.17 [24] for the A-allele of GCK rs1799884 and 0.54 [24] for the C-allele GCKR rs780094 in a Chinese population, our sample size has >90% power to detect a T2D risk under the prevalence of 0.1 with an odds ratio of 1.16 [43], 1.19 [31], 1.22 [25] and 1.18 [21] respectively, and a per-allele effect of increasing FPG by >0.068 (total QTL variance = 0.012) and >0.067 (total QTL variance = 0.012) mmol/l [31], [43] for rs10830963 and rs16856187 respectively, at the α level of 0.05.

All statistical analyses were performed using SAS v.9.1 (SAS Institute, Cary, NC, USA) or SPSS for Windows v.15 (SPSS, Chicago, IL, USA) unless specified otherwise. Two-tailed P values <0.05 were considered statistically significant.

Results

Associations with FPG, beta cell function and T2D

We have previously shown that the minor A-allele of GCK rs1799884 was associated with higher FPG, nevertheless, no association was detected for GCKR rs780049. In this study, we further observed consistent and significant association of the minor G-allele of MTNR1B rs10830963 (Beta±S.E. = 0.037±0.012 and P = 0.0034 in combined analysis) as well as the C-alleles of both G6PC2 rs16856187 (Beta±S.E. = 0.059±0.015 and P = 6.6×10−5 in combined analysis) and rs478333 (Beta±S.E. = 0.050±0.013 and P = 0.0002 in combined analysis) with increased FPG after adjustment for age, gender, BMI and/or study cohorts (Table 2 and 3).

[Figure omitted. See PDF.]

Table 2. Associations of MTNR1B rs10830963 with type 2 diabetes related traits in Chinese control subjects.

https://doi.org/10.1371/journal.pone.0011428.t002

[Figure omitted. See PDF.]

Table 3. Associations of G6PC2 rs16856187 and rs478333 with type 2 diabetes related traits in Chinese control subjects.

https://doi.org/10.1371/journal.pone.0011428.t003

In addition, association with reduced beta-cell function as assessed by HOMA-B was also observed for the A-allele of GCK rs1799884 (Beta±S.E. = −0.081±0.026 and P = 0.0015), as well as trend for associations with the G-allele of MTNR1B rs10830963 (Beta±S.E. = −0.037±0.019 and P = 0.0532) and the C-allele of G6PC2 rs478333 (Beta±S.E. = −0.039±0.021 and P = 0.0623) in the combined control samples (Tables 2, 3, 4).

[Figure omitted. See PDF.]

Table 4. Associations of GCK rs1799884 and GCKR rs780094 with type 2 diabetes related traits in Chinese control subjects.

https://doi.org/10.1371/journal.pone.0011428.t004

The associations of FPG with MTNR1B rs10830963 (P = 0.0162), G6PC2 rs16856187 (P = 0.0013) and rs478333 (P = 0.0019), as well as GCK rs1799884 with HOMA-B (P = 0.0095) in the combined control samples remained significant after controlling for FDR. None of the SNPs revealed association with T2D (Table S2), BMI, FPI or insulin sensitivity, as measured by HOMA-IR (Tables 2, 3, 4) or OGTT-based traits (Table S3).

Interaction and joint effect of genes on FPG, beta-cell function and T2D

We did not detect any novel pairwise interaction between genes on FPG level or beta-cell function in the combined healthy controls (data not shown), apart from the one previously reported between GCK rs1799884 and GCKR rs780094. We then examined the joint effects of selected SNPs from GCK, GCKR, MTNR1B, G6PC2 genes on FPG and beta-cell function, assuming that all risk alleles have similar effect sizes. Due to the relatively high linkage disequilibrium between G6PC2 rs16856187 and G6PC2 rs478333 (r2 = 0.62 in both HapMap CHB data and the present study), only the most significant SNP was included for the joint analysis of FPG or beta-cell function, respectively. We tested for the independence between loci by using all four corresponding loci in the regression models. All loci were independent (P<0.05) except for GCKR rs780094. Subjects with increasing number of risk alleles showed higher FPG concentration (P = 2.9×10−9) and lower value of HOMA-B (P = 1.1×10−3) (Figure 1A–B) in a dose-dependent manner. In addition, we did not find any association between T2D and combined gene variants (Table S2).

[Figure omitted. See PDF.]

Figure 1. Additive effects on fasting plasma glucose and HOMA beta-cell function.

A) Additive effect of the MTNR1B rs10830963, G6PC2 rs16856187, GCK rs1799884 and GCKR rs780094 variants on fasting plasma glucose and B) Additive effect of the MTNR1B rs10830963, G6PC2 rs478333, GCK rs1799884 and GCKR rs780094 variants on HOMA beta-cell function with adjustment for sex, age, BMI and study cohorts (adult or adolescent) in combined control subjects. Values are presented as mean (95% C.I.) according to the number of risk alleles.

https://doi.org/10.1371/journal.pone.0011428.g001

Meta-analyses of MTNR1B rs10830963 and G6PC2 rs16856187 with FPG

In our previous study, we have confirmed the association of GCK rs1799884 with FPG in a meta-analysis including both Europeans and Chinese populations. In the present study, meta-analysis of association of MTNR1B (rs10830963) in Europeans showed increases of 0.15 (0.11–0.19) and 0.29 (0.25–0.34) in (SMD) of FPG for CG and GG genotypes, respectively, when compared to the CC reference genotype (Figure S2). However, weaker and dominance effect was found in Chinese, with increases of 0.20 (0.11–0.28) and 0.23 (0.12–0.34) in SMD of FPG for CG and GG genotypes, respectively (Figure S2). In the combined meta-analysis for all European and Chinese cohorts, we confirmed the additive effect of the G-allele in MTNR1B rs10830963 with FPG. Furthermore, an additive trend of 0.15 (0.03–0.27) and 0.31 (0.19–0.44) increases in SMD of FPG for AC and CC genotypes, respectively, when compared to the AA reference genotype, was also observed for G6PC2 rs16856187 in Chinese populations (Figure S3). Due to significant heterogeneity amongst the study cohorts (P<0.1), the combined SMDs were calculated based on the random effect models, only using the fixed effect models for the association of MTNR1B rs10830963 in all Chinese cohorts (P>0.1) (Figure S3).

Discussion

Here we reported the association of rs10830963 in MTNR1B, rs16856187 and rs478333 in G6PC2, and rs1799884 in GCK with higher FPG and lower HOMA-B levels. Further analyses of the risk alleles (G-allele of rs10830963, C-alleles of both rs16856187 and rs478333, A-allele of rs1799884 and C-allele of GCKR rs780094) confirmed their joint effects on FPG and beta-cell function. These consistent findings from three independent cohorts strongly support the risk effects of these variants on GSIS to predispose hyperglycemia in Chinese.

Consistent with previous studies [9], [10], [28], [30], [32], [44], [45], [46], [47], we observed the individual and joint effects of risk alleles in MTNR1B, G6PC2, and GCK on FPG. Compared to the carriers with 0 or 1 alleles, each additional allele increases mean FPG level by 0.048 (0.032–0.064) mmol/l (Figure 1). This effect size is similar to those observed in Dutch (0.05 (0.04–0.07)) [32], French (0.07 (0.06–0.08) [9], and Japanese (0.055 (0.045–0.065)) [45] populations, despite the use of different risk variants. While GCK rs1799884 and MTNR1B rs10830963 are strongly associated to FPG in both Caucasian and Asian cohorts [21], [43], [45], [48], we and others have observed an Asian specific G6PC2 risk variant (rs16856187 in Hu et al [31] and the current study, and rs3755157 in Takeuchi et al [45], r2≥0.9) in addition to the Caucasian reported rs563694 (Figure S4). This suggests that while these loci are reproducibly associated to FPG across populations, as shown in our meta-analyses (Figures S2, S3), replication in multiple ethnicities could help to identify population specific risk variants and filter for causal variants. Since G6PC2 rs478333 is common in both Asian (0.29 in Hapmap CHB) and Caucasian (0.49 in HapMap CEU), its replication could provide new insight. Together, the Asian-specific rs16856187 and rs478333 and the Caucasian specific rs563694 (r2 = 0.02 and 0.03 to rs16856187 and rs47833, respectively) helped refined a 8.8 kb region of interest (Figure S4), which would be useful for future functional studies.

We further observed that these variants exerted individual and combined effects on beta-cell function, as estimated by the homeostasis model (HOMA-B). To our knowledge, this is the first study showing that the same risk alleles can jointly impair insulin secretion and elevate FPG level. Each allele decreases mean HOMA-B level by 0.04%, which may partially explain the concomitant increase of 0.048 mmol/l in mean FPG level (Figure 1). A recent GWAS meta-analysis involving ∼100,000 Europeans demonstrated that the same risk alleles in MTNR1B, G6PC2, and GCK were associated to FPG and HOMA-B at genome-wide significant levels [48]. Most of the 17 FPG-associated loci were also consistently associated to HOMA-B [48]. Our result and other literature support that impaired beta-cell function and hyperglycemia likely share the same underlying pathogenic mechanism.

Although we had sufficient power (>90%) to detect T2D risks with odds ratio ranging from 1.16 to 1.22 [21], [25], [31], [43], we did not detect T2D-associations for these four loci (P = 0.47–0.88). Several large-scale studies failed to find T2D-associations as well [28], [29], and even if found, their effects on T2D are shown to be much weaker than their effects on FPG [9], [10], [11], [21], [31], [32], [43]. Dupuis et al. estimated that MTNR1B, GCK and GCKR were associated to T2D with modest effect sizes of 1.06–1.09 [48], so our result may be explained by a lack of power due to the small sample size.

In pancreatic islets, glucose is phosphorylated by GCK into glucose-6-phosphate (G6P), committing it for glycolysis and the subsequent glucose-stimulated insulin secretion (GSIS). G6PC2 is hypothesized to counteract this process, which removes the phosphate group and releases glucose from the beta-cell [16]. MTNR1B may down regulate GCK expression and GSIS by lowering intracellular cAMP level [17], [49]. Indeed, GCK, G6PC2 and MTNR1B knock out mice demonstrated significantly lower FPG levels [18], [27], [50]. Thus, the coexistences of risk alleles in MTNR1B, G6PC2, and GCK may confer high melatonin level, low intra-islet glucose oxidation, and low GCK activity in carriers, causing decreased insulin secretion and increased FPG level as observed in this study. The low number of overlapping loci between FPG and T2D GWAS studies [48] suggested that genetic variants may disturb beta-cell function and affect physiological fasting glucose levels beneath the pathological thresholds of T2D.

In conclusion, we showed that risk alleles in GCK, GCKR, G6PC2, and MTNR1B exert joint effects on FPG and HOMA-B. The Asian-specific risk variants in G6PC2 may help to fine map the causal region within the gene (or possibly the G6PC2-ABCB11 region, given the proximity and strong linkage disequilibrium between the two genes). Concordant with previous studies, we assumed each allele contributes equal dosage, despite minor differences among their effect sizes. Some limitations of this study include using adolescents as controls, which may reduce our power as they may develop T2D later in life. This concern is partially alleviated by obtaining similar results compared to the Chinese and Caucasian adult cohorts (Figures S2, S3). Other studies using adolescent cohorts also reported consistent results [44]. Our study could be improved by using directly measured insulin data rather than surrogate measures such as HOMA-B and HOMA-IR, and increasing the sample size of our OGTT-based associations. Our results could be further improved by using the PACT method instead of FDR to correct for multiple comparisons, which considered the correlation structure among both SNPs and phenotypes and is less conservative [40]. Future studies in other populations would substantiate our finding.

Supporting Information

[Figure omitted. See PDF.]

Table S1.

Descriptions of studies.

https://doi.org/10.1371/journal.pone.0011428.s001

(0.13 MB DOC)

Table S2.

Associations of SNPs and risk allele scores with type 2 diabetes.

https://doi.org/10.1371/journal.pone.0011428.s002

(0.07 MB DOC)

Table S3.

Associations of MTNR1B rs10830963, GCK rs1799884 as well as G6PC2 rs16856187 and rs478333 with OGTT-based traits in combined Chinese control subjects (adults and adolescents).

https://doi.org/10.1371/journal.pone.0011428.s003

(0.07 MB DOC)

Figure S1.

Flow chart of literature search for studies on the association of fasting glucose with a) MTNR1B rs10830963 and b) G6PC2 rs560887/rs16856187.

https://doi.org/10.1371/journal.pone.0011428.s004

(0.16 MB DOC)

Figure S2.

Meta-analysis of associations of MTNR1B rs10830963 with fasting plasma glucose in European and Chinese populations.

https://doi.org/10.1371/journal.pone.0011428.s005

(0.06 MB DOC)

Figure S3.

Meta-analysis of associations of G6PC2 rs560887 and rs16856187 with fasting plasma glucose in European and Chinese populations, respectively.

https://doi.org/10.1371/journal.pone.0011428.s006

(0.06 MB DOC)

Figure S4.

Linkage disequilibrium for SNPs within the region near G6PC2 and ABCB11 at chromosome 2 between 169.47 Mb and 169.49 Mb.

https://doi.org/10.1371/journal.pone.0011428.s007

(0.12 MB DOC)

Acknowledgments

We are grateful to all study subjects who took part in these studies. We thank Ms. Cherry Chiu and Dr. Gary Wong for recruitment of study subjects, and Mr. Alex Ng and Ms. Patty Tse for technical assistance. We thank deCODE Genetics, Iceland, for help with genotyping of samples, and the CUHK Centre for Clinical Trials and Information Technology Services Centre for support of computing resources. Special thanks are extended to all nursing and medical staff at the PWH Diabetes and Endocrine Centre for their dedication and professionalism.

Author Contributions

Conceived and designed the experiments: MM WYS RCWM JCNC MCN. Performed the experiments: VKL SG. Analyzed the data: CHTT JSKH YW HML. Contributed reagents/materials/analysis tools: SG MM. Wrote the paper: CHTT JSKH. Recruitment of patients: YW.

Citation: Tam CHT, Ho JSK, Wang Y, Lee HM, Lam VKL, Germer S, et al. (2010) Common Polymorphisms in MTNR1B, G6PC2 and GCK Are Associated with Increased Fasting Plasma Glucose and Impaired Beta-Cell Function in Chinese Subjects. PLoS ONE5(7): e11428. https://doi.org/10.1371/journal.pone.0011428

References

1. (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care 29: Suppl 1S43–48.2006Diagnosis and classification of diabetes mellitus.Diabetes Care29Suppl 1S4348

2. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553.KG AlbertiPZ Zimmet1998Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.Diabet Med15539553

3. Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, et al. (2000) Impaired fasting glucose: how low should it go? Diabetes Care 23: 34–39.JE ShawPZ ZimmetAM HodgeM. de CourtenGK Dowse2000Impaired fasting glucose: how low should it go?Diabetes Care233439

4. Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708–723.N. UnwinJ. ShawP. ZimmetKG Alberti2002Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.Diabet Med19708723

5. Piche ME, Arcand-Bosse JF, Despres JP, Perusse L, Lemieux S, et al. (2004) What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care 27: 2470–2477.ME PicheJF Arcand-BosseJP DespresL. PerusseS. Lemieux2004What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose.Diabetes Care2724702477

6. Freeman MS, Mansfield MW, Barrett JH, Grant PJ (2002) Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. Diabet Med 19: 994–999.MS FreemanMW MansfieldJH BarrettPJ Grant2002Heritability of features of the insulin resistance syndrome in a community-based study of healthy families.Diabet Med19994999

7. Li JK, Ng MC, So WY, Chiu CK, Ozaki R, et al. (2006) Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2 diabetes mellitus. Diabetes Metab Res Rev 22: 46–52.JK LiMC NgWY SoCK ChiuR. Ozaki2006Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2 diabetes mellitus.Diabetes Metab Res Rev224652

8. Zhang S, Liu X, Yu Y, Hong X, Christoffel KK, et al. (2009) Genetic and Environmental Contributions to Phenotypic Components of Metabolic Syndrome: A Population-based Twin Study. Obesity (Silver Spring). S. ZhangX. LiuY. YuX. HongKK Christoffel2009Genetic and Environmental Contributions to Phenotypic Components of Metabolic Syndrome: A Population-based Twin Study.Obesity (Silver Spring)

9. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, et al. (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41: 89–94.N. Bouatia-NajiA. BonnefondC. Cavalcanti-ProencaT. SparsoJ. Holmkvist2009A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk.Nat Genet418994

10. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, et al. (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41: 77–81.I. ProkopenkoC. LangenbergJC FlorezR. SaxenaN. Soranzo2009Variants in MTNR1B influence fasting glucose levels.Nat Genet417781

11. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.E. ZegginiLJ ScottR. SaxenaBF VoightJL Marchini2008Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.Nat Genet40638645

12. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840–846.SE KahnRL HullKM Utzschneider2006Mechanisms linking obesity to insulin resistance and type 2 diabetes.Nature444840846

13. Issad T, Kuo M (2008) O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 19: 380–389.T. IssadM. Kuo2008O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity.Trends Endocrinol Metab19380389

14. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, et al. (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41: 82–88.V. LyssenkoCL NagornyMR ErdosN. WierupA. Jonsson2009Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.Nat Genet418288

15. Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, et al. (1993) Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest 92: 2092–2098.F. MatschinskyY. LiangP. KesavanL. WangP. Froguel1993Glucokinase as pancreatic beta cell glucose sensor and diabetes gene.J Clin Invest9220922098

16. Newgard CB, Lu D, Jensen MV, Schissler J, Boucher A, et al. (2002) Stimulus/secretion coupling factors in glucose-stimulated insulin secretion: insights gained from a multidisciplinary approach. Diabetes 51: Suppl 3S389–393.CB NewgardD. LuMV JensenJ. SchisslerA. Boucher2002Stimulus/secretion coupling factors in glucose-stimulated insulin secretion: insights gained from a multidisciplinary approach.Diabetes51Suppl 3S389393

17. Peschke E (2008) Melatonin, endocrine pancreas and diabetes. J Pineal Res 44: 26–40.E. Peschke2008Melatonin, endocrine pancreas and diabetes.J Pineal Res442640

18. Muhlbauer E, Gross E, Labucay K, Wolgast S, Peschke E (2009) Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol 606: 61–71.E. MuhlbauerE. GrossK. LabucayS. WolgastE. Peschke2009Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose.Eur J Pharmacol6066171

19. Van Schaftingen E (1994) Short-term regulation of glucokinase. Diabetologia 37: Suppl 2S43–47.E. Van Schaftingen1994Short-term regulation of glucokinase.Diabetologia37Suppl 2S4347

20. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331–1336.R. SaxenaBF VoightV. LyssenkoNP BurttPI de Bakker2007Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.Science31613311336

21. Qi Q, Wu Y, Li H, Loos RJ, Hu FB, et al. (2009) Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia 52: 834–843.Q. QiY. WuH. LiRJ LoosFB Hu2009Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population.Diabetologia52834843

22. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, et al. (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. NL BeerND TribbleLJ McCullochC. RoosPR Johnson2009The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.Hum Mol Genet

23. Rose CS, Ek J, Urhammer SA, Glumer C, Borch-Johnsen K, et al. (2005) A -30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. Diabetes 54: 3026–3031.CS RoseJ. EkSA UrhammerC. GlumerK. Borch-Johnsen2005A -30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites.Diabetes5430263031

24. Tam CH, Ma RC, So WY, Wang Y, Lam VK, et al. (2009) Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents. Diabetes 58: 765–769.CH TamRC MaWY SoY. WangVK Lam2009Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents.Diabetes58765769

25. Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, et al. (2008) Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 57: 244–254.M. VaxillaireJ. VeslotC. DinaC. ProencaS. Cauchi2008Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study.Diabetes57244254

26. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, et al. (1993) Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 328: 697–702.P. FroguelH. ZoualiN. VionnetG. VelhoM. Vaxillaire1993Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.N Engl J Med328697702

27. Wang Y, Flemming BP, Martin CC, Allen SR, Walters J, et al. (2008) Long-range enhancers are required to maintain expression of the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse islets in vivo. Diabetes 57: 133–141.Y. WangBP FlemmingCC MartinSR AllenJ. Walters2008Long-range enhancers are required to maintain expression of the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse islets in vivo.Diabetes57133141

28. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, et al. (2008) A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320: 1085–1088.N. Bouatia-NajiG. RocheleauL. Van LommelK. LemaireF. Schuit2008A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels.Science32010851088

29. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, et al. (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118: 2620–2628.WM ChenMR ErdosAU JacksonR. SaxenaS. Sanna2008Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels.J Clin Invest11826202628

30. Rose CS, Grarup N, Krarup NT, Poulsen P, Wegner L, et al. (2009) A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. Diabetologia 52: 2122–2129.CS RoseN. GrarupNT KrarupP. PoulsenL. Wegner2009A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads.Diabetologia5221222129

31. Hu C, Zhang R, Wang C, Ma X, Fang Q, et al. (2009) A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia 52: 451–456.C. HuR. ZhangC. WangX. MaQ. Fang2009A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population.Diabetologia52451456

32. Reiling E, van 't Riet E, Groenewoud MJ, Welschen LM, van Hove EC, et al. (2009) Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. Diabetologia. E. ReilingE. van 't RietMJ GroenewoudLM WelschenEC van Hove2009Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk.Diabetologia

33. Ng MC, Park KS, Oh B, Tam CH, Cho YM, et al. (2008) Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes 57: 2226–2233.MC NgKS ParkB. OhCH TamYM Cho2008Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians.Diabetes5722262233

34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.DR MatthewsJP HoskerAS RudenskiBA NaylorDF Treacher1985Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia28412419

35. Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11: 286–292.DI PhillipsPM ClarkCN HalesC. Osmond1994Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.Diabet Med11286292

36. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462–1470.M. MatsudaRA DeFronzo1999Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.Diabetes Care2214621470

37. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.S. PurcellB. NealeK. Todd-BrownL. ThomasMA Ferreira2007PLINK: a tool set for whole-genome association and population-based linkage analyses.Am J Hum Genet81559575

38. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.DF StroupJA BerlinSC MortonI. OlkinGD Williamson2000Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.JAMA28320082012

39. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279–284.Y. BenjaminiD. DraiG. ElmerN. KafkafiI. Golani2001Controlling the false discovery rate in behavior genetics research.Behav Brain Res125279284

40. Conneely KN, Boehnke M (2007) So Many Correlated Tests, So Little Time! Rapid Adjustment of P Values for Multiple Correlated Tests. Am J Hum Genet 81: KN ConneelyM. Boehnke2007So Many Correlated Tests, So Little Time! Rapid Adjustment of P Values for Multiple Correlated Tests.Am J Hum Genet81

41. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.R. DerSimonianN. Laird1986Meta-analysis in clinical trials.Control Clin Trials7177188

42. Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149–150.S. PurcellSS ChernyPC Sham2003Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.Bioinformatics19149150

43. Ronn T, Wen J, Yang Z, Lu B, Du Y, et al. (2009) A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia 52: 830–833.T. RonnJ. WenZ. YangB. LuY. Du2009A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals.Diabetologia52830833

44. Kelliny C, Ekelund U, Andersen LB, Brage S, Loos RJ, et al. (2009) Common genetic determinants of glucose homeostasis in healthy children: the European Youth Heart Study. Diabetes 58: 2939–2945.C. KellinyU. EkelundLB AndersenS. BrageRJ Loos2009Common genetic determinants of glucose homeostasis in healthy children: the European Youth Heart Study.Diabetes5829392945

45. Takeuchi F, Katsuya T, Chakrewarthy S, Yamamoto K, Fujioka A, et al. Common variants at the GCK, GCKR, G6PC2-ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations. Diabetologia 53: 299–308.F. TakeuchiT. KatsuyaS. ChakrewarthyK. YamamotoA. FujiokaCommon variants at the GCK, GCKR, G6PC2-ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations.Diabetologia53299308

46. Sparso T, Bonnefond A, Andersson E, Bouatia-Naji N, Holmkvist J, et al. (2009) G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes 58: 1450–1456.T. SparsoA. BonnefondE. AnderssonN. Bouatia-NajiJ. Holmkvist2009G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans.Diabetes5814501456

47. Langenberg C, Pascoe L, Mari A, Tura A, Laakso M, et al. (2009) Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. Diabetologia 52: 1537–1542.C. LangenbergL. PascoeA. MariA. TuraM. Laakso2009Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response.Diabetologia5215371542

48. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105–116.J. DupuisC. LangenbergI. ProkopenkoR. SaxenaN. Soranzo2010New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.Nat Genet42105116

49. Fernandez-Mejia C, Vega-Allende J, Rojas-Ochoa A, Rodriguez-Dorantes M, Romero-Navarro G, et al. (2001) Cyclic adenosine 3′,5′-monophosphate increases pancreatic glucokinase activity and gene expression. Endocrinology 142: 1448–1452.C. Fernandez-MejiaJ. Vega-AllendeA. Rojas-OchoaM. Rodriguez-DorantesG. Romero-Navarro2001Cyclic adenosine 3′,5′-monophosphate increases pancreatic glucokinase activity and gene expression.Endocrinology14214481452

50. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, et al. (1995) Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell 83: 69–78.A. GrupeB. HultgrenA. RyanYH MaM. Bauer1995Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis.Cell836978